Semaglutide
Treatment for Metabolic Syndrome
Typical Dosage: 0.25mg-2.4mg weekly subcutaneous injection
Effectiveness
88%
Safety Score
60%
Clinical Trials
18
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
0.25mg-2.4mg weekly subcutaneous injection
Time to Effect
4-8 weeks for initial effects, 6-12 months for maximal weight loss
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$13,500
Monitoring:$300
Side Effect Mgmt:$150
Total Annual:$13,950
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$150,000/QALY
QALYs Gained
1.1
Outcome-Based Costs
Cost per Responder
$16,412
Cost per Remission
$34,875
Comparison vs Metformin
Cost Difference
+$13,450/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Semaglutide Outcomes
for Metabolic Syndrome
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+85%
Remission Rate
+40%
Common Side Effects
Nausea
+45%
Vomiting
+20%
Diarrhea/Constipation
+25%
Pancreatitis (rare)
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
12 active trials recruiting for Semaglutide in Metabolic Syndrome
Semaglutide 2.4 mg in Patients With Poor Weight-loss
NCT05073835ACTIVE NOT RECRUITINGPHASE3
70 participants
INTERVENTIONAL
London, United Kingdom
Started: Nov 1, 2022
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
NCT06410352RECRUITINGPHASE4
220 participants
INTERVENTIONAL
Astana, Kazakhstan
Started: Mar 1, 2024
COMMETS- Combination MCI Metabolic Syndrome
NCT06072963RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Ramat Gan, Israel
Started: Jan 30, 2024
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
NCT06896981RECRUITINGPHASE2, PHASE3
30 participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Feb 1, 2025
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853RECRUITINGPHASE3
80 participants
INTERVENTIONAL
Aurora, United States
Started: Nov 3, 2023
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
NCT07361874RECRUITINGNA
75 participants
INTERVENTIONAL
Dallas, United States
Started: Mar 5, 2026
Effects of Semaglutide in HIV-Associated Lipohypertrophy
NCT04019197ACTIVE NOT RECRUITINGPHASE2
108 participants
INTERVENTIONAL
Cleveland, United States +1 more
Started: May 16, 2019
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
NCT07188545ACTIVE NOT RECRUITING
23.3M participants
OBSERVATIONAL
Columbus, United States
Started: Sep 15, 2025
Anti-obesity Pharmacotherapy and Inflammation
NCT05756764ACTIVE NOT RECRUITING
30 participants
OBSERVATIONAL
New Orleans, United States +1 more
Started: Jun 1, 2023
Metabolic Surgery for Atrial Fibrillation Elimination
NCT07027969NOT YET RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Cleveland, United States
Started: Nov 1, 2026
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
NCT07169136RECRUITING
20 participants
OBSERVATIONAL
Jacksonville, United States
Started: Sep 11, 2025
Reversal to Normoglycemia by Treating Prediabetes
NCT07392151NOT YET RECRUITINGPHASE3
158 participants
INTERVENTIONAL
Aarhus N, Denmark
Started: Feb 1, 2026
Completed Clinical Trials
4 completed trials for Semaglutide in Metabolic Syndrome
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
NCT04216589COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Birmingham, United States +8 more
Started: Feb 19, 2021
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
NCT07281196COMPLETED
15 participants
OBSERVATIONAL
Shanghai, China
Started: Jan 1, 2025
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
NCT05193578COMPLETEDPHASE2
154 participants
INTERVENTIONAL
Odense, Denmark
Started: Jan 1, 2022
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
NCT06027567COMPLETEDPHASE4
38 participants
INTERVENTIONAL
Odense, Denmark +1 more
Started: Sep 2, 2022
Showing 20 of 21 total trials